Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
Launched by M.D. ANDERSON CANCER CENTER · Jul 16, 2020
Trial Information
Current as of November 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether a specially designed video can help reduce anxiety for patients with brain tumors, such as glioblastoma and other types of gliomas, and their caregivers during radiation treatment. The video will show information about specific symptoms and side effects related to their type of tumor, aiming to help patients feel more at ease before, during, and after their treatment. By addressing anxiety, the hope is to improve the overall quality of life for both patients and their caregivers.
To participate, patients must be adults diagnosed with a specific type of glioma and scheduled for a 6-week course of radiation therapy after surgery. They should also have a recent MRI of their brain. Caregivers who accompany these patients can join the study too, as long as they can complete questionnaires in English. Participants can expect to watch the video and provide feedback through questionnaires to help researchers understand its impact on anxiety levels. It’s important to note that individuals with significant cognitive or psychiatric issues that affect their ability to complete these questionnaires will not be eligible for the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PATIENT ELIGIBILITY CRITERIA: Adult patients with newly diagnosed glioma (World Health Organization \[WHO\] grade 2-4) who are planned for a 6-week course of radiotherapy after surgery
- • PATIENT ELIGIBILITY CRITERIA: Able to complete questionnaires in English
- • PATIENT ELIGIBILITY CRITERIA: Has a post-operative diagnostic magnetic resonance imaging (MRI) of the brain with and without contrast acquired within 4 weeks of the start of radiotherapy
- • CAREGIVER ELIGIBILITY CRITERIA: Adult caregiver (\>= 18 years) who is accompanying an eligible patient consented to the study
- • CAREGIVER ELIGIBILITY CRITERIA: The patient who the caregiver is accompanying is consented for participation on the study
- • CAREGIVER ELIGIBILITY CRITERIA: Able and willing to complete questionnaires in English
- Exclusion Criteria:
- • PATIENT ELIGIBILITY CRITERIA: Significant cognitive or psychiatric symptoms that prevent the ability to complete the questionnaires as determined by the assessing staff in the pre-intervention evaluation
- • PATIENT ELIGIBILITY CRITERIA: Poor performance status (Karnofsky performance status \[KPS\] \< 60) that prevent the ability to complete the questionnaires
- • CAREGIVER ELIGIBILITY CRITERIA: Significant cognitive or psychiatric symptoms that prevent the ability to complete the questionnaires as determined by the assessing staff in the pre-intervention evaluation
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Caroline Chung
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials